Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease

References

• Baldwin SL, Larsen SE, Ordway D, et al. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl Trop Dis. 2019;13(2):e0007083. DOI:10.1371/journal.pntd.0007083.
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535. DOI:10.1183/13993003.00535-2020.
   PubMed Web of Science ®Google Scholar
• To K, Cao R, Yegiazaryan A, et al. General overview of nontuberculous mycobacteria opportunistic pathogens: Mycobacterium avium and Mycobacterium abscessus. J Clin Med. 2020 Aug 6 9;(8)2541. DOI:10.3390/jcm9082541.
   PubMed Web of Science ®Google Scholar
• Faria S, Joao I, Jordao L. General overview on nontuberculous mycobacteria, biofilms, and human infection. J Pathog. 2015;2015:809014. DOI:10.1155/2015/809014.
   PubMed Web of Science ®Google Scholar
• Lee YM, Kim MJ, Kim YJ. Increasing trend of nontuberculous mycobacteria isolation in a referral clinical laboratory in South Korea. Medicina (Kaunas). 2021 Jul 16;57(7). DOI:10.3390/medicina57070720.
   Web of Science ®Google Scholar
• Donohue MJ, Wymer L. Increasing prevalence rate of nontuberculous mycobacteria infections in five states, 2008-2013. Ann Am Thorac Soc. 2016 Dec;13(12):2143–2150. DOI:10.1513/AnnalsATS.201605-353OC.
   PubMed Web of Science ®Google Scholar
• Schildkraut JA, Gallagher J, Morimoto K, et al. Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation. Respir Med. 2020;173:106164. DOI:10.1016/j.rmed.2020.106164.
   PubMed Web of Science ®Google Scholar
• Jeon D. Infection source and epidemiology of nontuberculous mycobacterial lung disease. Tuberc Respir Dis (Seoul). 2019 Apr;82(2):94–101. DOI:10.4046/trd.2018.0026.
   PubMed Web of Science ®Google Scholar
• Huang HL, Cheng MH, Lu PL, et al. Epidemiology and predictors of NTM pulmonary infection in Taiwan - a retrospective, five-year multicenter study. Sci Rep. 2017 Nov 24;7(1):16300. DOI:10.1038/s41598-017-16559-z.
   PubMedGoogle Scholar
• Morimoto K, Iwai K, Uchimura K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014;11(1):1–8. DOI:10.1513/AnnalsATS.201303-067OC.
   PubMedGoogle Scholar
• van Ingen J, Obradovic M, Hassan M, et al. Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med. 2021;15(11):1387–1401. DOI:10.1080/17476348.2021.1987891.
   PubMed Web of Science ®Google Scholar
• Wallace RJ Jr., Brown-Elliott BA, McNulty S, et al. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest. 2014;146(2):276–282. DOI:10.1378/chest.13-2538.
   PubMed Web of Science ®Google Scholar
• Griffith DE. Treatment of Mycobacterium avium complex (MAC). Semin Respir Crit Care Med. 2018 Jun;39(3):351–361. DOI: 10.1055/s-0038-1660472.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Adjemian J, Brown-Elliott BA, et al. Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2015 Sep 15 192;(6)754–760. DOI:10.1164/rccm.201503-0444OC
   PubMed Web of Science ®Google Scholar
• Pennington KM, Vu A, Challener D, et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis. 2021 May 8;24:100244. DOI:10.1016/j.jctube.2021.100244 .
   PubMedGoogle Scholar
• Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018 May 3; 18(1):206. DOI:10.1186/s12879-018-3113-x.
   PubMed Web of Science ®Google Scholar
• Jhun BW, Kim SY, Moon SM, et al. Development of macrolide resistance and reinfection in refractory Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2018 Nov 15;198(10):1322–1330. DOI:10.1164/rccm.201802-0321OC.
   PubMed Web of Science ®Google Scholar
• Park YE, Chong YP, Kim YJ, et al. Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease. J Thorac Dis. 2020;12(3):338–348. DOI:10.21037/jtd.2020.01.39.
   PubMed Web of Science ®Google Scholar
• Nasiri MJ, Ebrahimi G, Arefzadeh S, et al. Antibiotic therapy success rate in pulmonary Mycobacterium avium complex: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2020;18(3):263–273. DOI:10.1080/14787210.2020.1720650.
   PubMed Web of Science ®Google Scholar
• Moon SM, Park HY, Kim SY, et al. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016;60(11):6758–6765. DOI:10.1128/AAC.01240-16.
   PubMed Web of Science ®Google Scholar
• Morimoto K, Namkoong H, Hasegawa N, et al. Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases. Ann Am Thorac Soc. 2016;13(11):1904–1911. DOI:10.1513/AnnalsATS.201604-246OC.
   PubMed Web of Science ®Google Scholar
• Pan SW, Shu CC, Feng JY, et al. Microbiological persistence in patients with Mycobacterium avium complex lung disease: the predictors and the impact on radiographic progression. Clin Infect Dis. 2017 Sep 15;65(6):927–934. DOI:10.1093/cid/cix479.
   PubMed Web of Science ®Google Scholar
• Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006 Oct 15;174(8):928–934. DOI:10.1128/AAC.01240-16.
   PubMed Web of Science ®Google Scholar
• Bermudez LE, Nash K, Petrofsky M, et al. Clarithromycin-resistant Mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. Antimicrob Agents Chemother. 2000;44(10):2619–2622. DOI:10.1128/AAC.44.10.2619-2622.2000.
   PubMed Web of Science ®Google Scholar
• Larsen SE, Reese VA, Pecor T, et al. Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models. Sci Rep. 2021 Apr 27 11;(1)9040. DOI:10.1038/s41598-021-88291-8
   PubMed Web of Science ®Google Scholar
• Saunders BM, Zhan Y, Cheers C. Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Infect Immun. 1995 Oct;63(10):4011–4015. DOI:10.1128/iai.63.10.4011-4015.1995.
   PubMed Web of Science ®Google Scholar
• Martin E, Kamath AT, Briscoe H, et al. The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guerin) in protecting against systemic Mycobacterim avium infection. Immunology. 2003;109(2):308–314. DOI:10.1046/j.1365-2567.2003.01660.x.
   PubMed Web of Science ®Google Scholar
• Appelberg R. Pathogenesis of Mycobacterium avium infection: typical responses to an atypical mycobacterium? Immunol Res. 2006;35(3):179–190. DOI:10.1385/IR:35:3:179.
   PubMed Web of Science ®Google Scholar
• Darleguy A, Bost-Bru C, Pagnier A, et al. Mendelian susceptibility to mycobacterial disease: a case report of disseminated infection due to Mycobacterium avium. Arch Pediatr. 2013;20(7):758–761. DOI:10.1016/j.arcped.2013.04.005.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Pai G, Deswarte C, et al. Disseminated Mycobacterium avium complex infection in a child with partial dominant interferon gamma receptor 1 deficiency in India. J Clin Immunol. 2015;35(5):459–462. DOI:10.1007/s10875-015-0173-1.
   PubMed Web of Science ®Google Scholar
• Yoo JW, Jo KW, Kang BH, et al. Mycobacterial diseases developed during anti-tumour necrosis factor-alpha therapy. Eur Respir J. 2014;44(5):1289–1295. DOI:10.1183/09031936.00063514.
   PubMed Web of Science ®Google Scholar
• Lim A, Allison C, Price P, et al. Susceptibility to pulmonary disease due to Mycobacterium avium-intracellulare complex may reflect low IL-17 and high IL-10 responses rather than Th1 deficiency. Clin Immunol. 2010;137(2):296–302. DOI:10.1016/j.clim.2010.07.011.
   PubMed Web of Science ®Google Scholar
• Kim SY, Koh WJ, Park HY, et al. Changes in serum immunomolecules during antibiotic therapy for Mycobacterium avium complex lung disease. Clin Exp Immunol. 2014;176(1):93–101. DOI:10.1111/cei.12253.
   PubMed Web of Science ®Google Scholar
• Bak Y, Park SC, Shim D, et al. Exacerbation of Mycobacterium avium pulmonary infection by comorbid allergic asthma is associated with diminished mycobacterium-specific Th17 responses. Virulence. 2021;12(1):2546–2561. DOI:10.1080/21505594.2021.1979812.
   PubMed Web of Science ®Google Scholar
• Kannan N, Haug M, Steigedal M, et al. Mycobacterium smegmatis vaccine vector elicits CD4+ Th17 and CD8+ Tc17 T cells with therapeutic potential to infections with Mycobacterium avium. Front Immunol. 2020;11:1116. DOI:10.3389/fimmu.2020.01116.
   PubMed Web of Science ®Google Scholar
• Counoupas C, Ferrell KC, Ashhurst A, et al. Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis. NPJ Vaccines. 2020 Nov 12;5(1):105. DOI:10.1038/s41541-020-00255-7.
   PubMed Web of Science ®Google Scholar
• Scriba TJ, Netea MG, Ginsberg AM. Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Semin Immunol. 2020 Aug 1;50:101431. DOI:10.1016/j.smim.2020.101431 .
   PubMed Web of Science ®Google Scholar
• Shanmugasundaram U, Bucsan AN, Ganatra SR, et al. Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment. JCI Insight. 2020 Jul 23;5(14). DOI:10.1172/jci.insight.137858.
   PubMed Web of Science ®Google Scholar
• Choi HG, Kwon KW, Choi S, et al. Antigen-pecific IFN-γ/IL-17-co-producing CD4+ T-cells are the determinants for protective efficacy of tuberculosis subunit vaccine. Vaccines (Basel). 2020 Jun 11;8(2). DOI:10.3390/vaccines8020300.
   Web of Science ®Google Scholar
• Park SM, Omatsu T, Zhao Y, et al. T cell fate following Salmonella infection is determined by a STING-IRF1 signaling axis in mice. Commun Biol. 2019;2(1):464. DOI:10.1038/s42003-019-0701-2.
   PubMedGoogle Scholar
• Van Dis E, Sogi KM, Rae CS, et al. STING-activating adjuvants elicit a Th17 immune response and protect against Mycobacterium tuberculosis infection. Cell Rep. 2018 May 1;23(5):1435–1447. DOI:10.1016/j.celrep.2018.04.003.
   PubMed Web of Science ®Google Scholar
• Coler RN, Bertholet S, Pine SO, et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis. 2013 Apr 15;207(8):1242–1252. DOI:10.1093/infdis/jis425.
   PubMed Web of Science ®Google Scholar
• Larsen SE, Baldwin SL, Orr MT, et al. Enhanced anti-Mycobacterium tuberculosis immunity over time with combined drug and immunotherapy treatment. Vaccines (Basel). 2018 May 24;6(2). DOI:10.3390/vaccines6020030.
   PubMed Web of Science ®Google Scholar
• Labro MT, Abdelghaffar H. Immunomodulation by macrolide antibiotics. J Chemother. 2001 Feb;13(1):3–8. DOI:10.1179/joc.2001.13.1.3.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Ziesenitz VC, Curtis N, et al. The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms. Front Immunol. 2018;9:302. DOI:10.3389/fimmu.2018.00302.
   PubMed Web of Science ®Google Scholar
• Lee JM, Park J, Choi S, et al. A clofazimine-containing regimen confers improved treatment outcomes in macrophages and in a murine model of chronic progressive pulmonary infection caused by the Mycobacterium avium complex. Front Microbiol. 2021 Jan 14;11:626216. DOI:10.3389/fmicb.2020.626216.
   PubMed Web of Science ®Google Scholar
• Shin SJ, Cho D, Collins MT. Diagnosis of bovine paratuberculosis by a novel enzyme-linked immunosorbent assay based on early secreted antigens of Mycobacterium avium subsp. Paratuberculosis. Clin Vaccine Immunol. 2008 Aug;15(8):1277–1281. DOI:10.1128/CVI.00105-08.
   PubMedGoogle Scholar
• Wynne JW, Shiell BJ, Colgrave ML, et al. Production and proteomic characterisation of purified protein derivative from Mycobacterium avium subsp. Paratuberculosis. Proteome Sci. 2012 Mar 26;10(1):22. DOI:10.1186/1477-5956-10-22.
   PubMedGoogle Scholar
• Jeon BY, Kwak J, Lee SS, et al. Comparative analysis of immune responses to Mycobacterium abscessus infection and its antigens in two murine models. J Microbiol. 2009;47(5):633–640. DOI:10.1007/s12275-009-0139-1.
   PubMed Web of Science ®Google Scholar
• Kwon KW, Lee A, Larsen SE, et al. Long-Term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Sci Rep. 2019Oct 29;9(1)15560. DOI:10.1038/s41598-019-52146-0.
   PubMedGoogle Scholar
• Choi HH, Kwon KW, Han SJ, et al. PPE39 of the Mycobacterium tuberculosis strain Beijing/K induces Th1-cell polarization through dendritic cell maturation. J Cell Sci. 2019 Sep 5;132(17). DOI:10.1242/jcs.228700.
   Web of Science ®Google Scholar
• Das S, Marin ND, Esaulova E, et al. Lung epithelial signaling mediates early vaccine-induced CD4+ T cell activation and Mycobacterium tuberculosis control. mBio. 2021 Aug 31;12(4):e0146821. DOI:10.1128/mBio.01468-21.
   PubMed Web of Science ®Google Scholar
• Griffiths KL, Ahmed M, Das S, et al. Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy. Nat Commun. 2016 Dec 22; 7(1)13894. DOI:10.1038/ncomms13894.
   PubMedGoogle Scholar
• Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007;8(4):369–377. DOI:10.1038/ni1449.
   PubMed Web of Science ®Google Scholar
• Gopal R, Lin Y, Obermajer N, et al. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol. 2012;42(2):364–373. DOI:10.1002/eji.201141569.
   PubMed Web of Science ®Google Scholar
• Roque S, Nobrega C, Appelberg R, et al. IL-10 underlies distinct susceptibility of BALB/c and C57BL/6 mice to Mycobacterium avium infection and influences efficacy of antibiotic therapy. J Immunol. 2007 Jun 15;178(12)8028–8035. DOI:10.4049/jimmunol.178.12.8028.
   PubMed Web of Science ®Google Scholar
• Andrejak C, Almeida DV, Tyagi S, et al. Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations. Antimicrob Agents Chemother. 2015;59(4):2129–2135. DOI:10.1128/AAC.04841-14.
   PubMed Web of Science ®Google Scholar
• Li H, Javid B. Antibodies and tuberculosis: finally coming of age? Nat Rev Immunol. 2018 Sep;18(9):591–596. DOI:10.1038/s41577-018-0028-0.
   PubMed Web of Science ®Google Scholar
• Fletcher HA, Snowden MA, Landry B, et al. T-Cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun. 2016 Apr 12;7(1):11290. DOI:10.1038/ncomms11290.
   PubMedGoogle Scholar
• Stevens TL, Bossie A, Sanders VM, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988 Jul 21;334(6179):255–258. DOI:10.1038/334255a0.
   PubMed Web of Science ®Google Scholar
• Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. J Infect Dis. 1993 Jun 1;167(6):1481–1497. DOI:10.1093/infdis/167.6.1481.
   PubMed Web of Science ®Google Scholar
• Pais TF, Cunha JF, Appelberg R. Antigen specificity of T-cell response to Mycobacterium avium infection in mice. Infect Immun. 2000 Aug;68(8):4805–4810. DOI:10.1128/IAI.68.8.4805-4810.2000.
   PubMed Web of Science ®Google Scholar
• Cerqueira-Rodrigues B, Mendes A, Correia-Neves M, et al. Ag85-focused T-cell immune response controls Mycobacterium avium chronic infection. PLoS One. 2018;13(3):e0193596. DOI:10.1371/journal.pone.0193596.
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol. 2001;19(1):93–129. DOI:10.1146/annurev.immunol.19.1.93.
   PubMed Web of Science ®Google Scholar
• Lindenstrom T, Agger EM, Korsholm KS, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol. 2009 Jun 15;182(12):8047–8055. DOI:10.4049/jimmunol.0801592.
   PubMed Web of Science ®Google Scholar
• Lewinsohn DA, Lewinsohn DM, Scriba TJ. Polyfunctional CD4+ T cells as targets for tuberculosis vaccination. Front Immunol. 2017;8:1262. DOI:10.3389/fimmu.2017.01262.
   PubMed Web of Science ®Google Scholar
• Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445–489. DOI:10.1146/annurev-immunol-030409-101212.
   PubMed Web of Science ®Google Scholar
• Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis. 2015 Aug;15(8):968–980. DOI:10.1016/S1473-3099(15)00089-4. Epub 2015 Jun 3.
   PubMed Web of Science ®Google Scholar
• Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998 May 29;280(5368):1432–1435. DOI:10.1126/science.280.5368.1432.
   PubMed Web of Science ®Google Scholar
• Patel SY, Ding L, Brown MR, et al. Anti-IFN-γ autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol. 2005 Oct 1;175(7):4769–4776. DOI:10.4049/jimmunol.175.7.4769.
   PubMed Web of Science ®Google Scholar
• Verma D, Stapleton M, Gadwa J, et al. Mycobacterium avium infection in a C3HeB/FeJ mouse model. Front Microbiol. 2019;10:693. DOI:10.3389/fmicb.2019.00693.
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an Official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020 Aug 14;71(4):e1–e36. DOI:10.1093/cid/ciaa241.
   PubMed Web of Science ®Google Scholar
• Hwang JA, Kim S, Jo KW, et al. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J. 2017;49(3):1600537. DOI:10.1183/13993003.00537-2016.
   PubMed Web of Science ®Google Scholar
• Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004 Aug;126(2):566–581. DOI:10.1378/chest.126.2.566.
   PubMed Web of Science ®Google Scholar
• Matsuyama M, Ishii Y, Sakurai H, et al. Overexpression of RORγt enhances pulmonary inflammation after infection with Mycobacterium avium. PLoS One. 2016;11(1):e0147064. DOI:10.1371/journal.pone.0147064.
   PubMed Web of Science ®Google Scholar
• Zeng M, Li ZY, Ma J, et al. Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: an explant model study. BMC Immunol. 2015 Jun 6; 16(1):37. DOI:10.1186/s12865-015-0096-x.
   PubMedGoogle Scholar
• Tsiakos K, Tsakiris A, Tsibris G, et al. Early start of oral clarithromycin is associated with better outcome in COVID-19 of moderate severity: the ACHIEVE open-label single-arm trial. Infect Dis Ther. 2021;10(4):2333–2351. DOI:10.1007/s40121-021-00505-8.
   PubMed Web of Science ®Google Scholar
• Takemori N, Ooi HK, Imai G, et al. Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma. Ecancermedicalscience. 2020;14:1088. DOI:10.3332/ecancer.2020.1088.
   PubMed Web of Science ®Google Scholar
• Sugiyama K, Shirai R, Mukae H, et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol. 2007;147(3):540–546. DOI:10.1111/j.1365-2249.2007.03299.x.
   PubMed Web of Science ®Google Scholar
• Ryndak MB, Laal S. Mycobacterium tuberculosis primary infection and dissemination: a critical role for alveolar epithelial cells. Front Cell Infect Microbiol. 2019 Aug 21;9:299. DOI:10.3389/fcimb.2019.00299.
   PubMed Web of Science ®Google Scholar
• Costa DL, Amaral EP, Namasivayam S, et al. Enhancement of CD4+ T cell function as a strategy for improving antibiotic therapy efficacy in Tuberculosis: does it work? Front Cell Infect Microbiol. 2021;11:672527. DOI:10.3389/fcimb.2021.672527.
   PubMed Web of Science ®Google Scholar
• Frimpong M, Agbavor B, Duah MS, et al. Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: relationship to bacterial load. PLoS Negl Trop Dis. 2019;13(8):e0007689. DOI:10.1371/journal.pntd.0007689.
   PubMed Web of Science ®Google Scholar
• Lee JY. Diagnosis and treatment of extrapulmonary tuberculosis. Tuberc Respir Dis (Seoul). 2015 Apr;78(2):47–55. DOI:10.4046/trd.2015.78.2.47.
   PubMed Web of Science ®Google Scholar
• O’-Brien DP, Robson ME, Callan PP, et al. “Paradoxical” immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust. 2009 Nov 16;191(10):564–566. DOI:10.5694/j.1326-5377.2009.tb03313.x.
   PubMed Web of Science ®Google Scholar
• Sambourg E, Dufour J, Edouard S, et al. Paradoxical reactions and responses during antibiotic treatment for Mycobacterium ulcerans infection (Buruli ulcer). Four cases from French Guiana. Ann Dermatol Venereol. 2014;141(6–7):413–418. DOI:10.1016/j.annder.2014.01.010.
   PubMed Web of Science ®Google Scholar
• Hui SH, Noonan L, Chavada R. Post liposuction Mycobacterium abscessus surgical site infection in a returned medical tourist complicated by a paradoxical reaction during treatment. Infect Dis Rep. 2015 Dec 22; 7(4):6304. DOI:10.4081/idr.2015.6304.
   PubMedGoogle Scholar
• Huh J-Y, Kwon BS, Park YE, et al. Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease. Eur Respir J. 2020;56(suppl 64):2360. DOI:10.1183/13993003.congress-2020.2360.
   Google Scholar
• Smibert OC, Trubiano JA, Cross GB, et al. Short communication: Mycobacterium avium complex infection and immune reconstitution inflammatory syndrome remain a challenge in the era of effective antiretroviral therapy. AIDS Res Hum Retroviruses. 2017;33(12):1202–1204. DOI:10.1089/aid.2017.0030.
   PubMed Web of Science ®Google Scholar
• Barber DL, Andrade BB, McBerry C, et al. Role of IL-6 in Mycobacterium avium–associated immune reconstitution inflammatory syndrome. J Immunol. 2014 Jan 15;192(2)676–682. DOI:10.4049/jimmunol.1301004.
   PubMed Web of Science ®Google Scholar
• Rosseels V, Marche S, Roupie V, et al. Members of the 30- to 32-kilodalton mycolyl transferase family (Ag85) from culture filtrate of Mycobacterium avium subsp. paratuberculosis are immunodominant Th1-type antigens recognized early upon infection in mice and cattle. Infect Immun. 2006;74(1):202–212. DOI:10.1128/IAI.74.1.202-212.2006.
   PubMed Web of Science ®Google Scholar
• Scriba TJ, Coussens AK, Fletcher HA. Human immunology of tuberculosis. Microbiol Spectr. 2017;5(1). DOI:10.1128/microbiolspec.TBTB2-0016-2016.
   PubMed Web of Science ®Google Scholar
• Vekemans J, Brennan MJ, Hatherill M, et al. Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: key considerations from World Health Organization consultations. Vaccine. 2020 Jan 10;38(2):135–142. DOI:10.1016/j.vaccine.2019.10.072.
   PubMed Web of Science ®Google Scholar
• Papadopoulou G, Xanthou G. Metabolic rewiring: a new master of Th17 cell plasticity and heterogeneity. Febs J. 2021 Apr 1. DOI:10.1111/febs.15853.
   PubMed Web of Science ®Google Scholar
• Hoe E, Anderson J, Nathanielsz J, et al. The contrasting roles of Th17 immunity in human health and disease. Microbiol Immunol. 2017;61(2):49–56. DOI:10.1111/1348-0421.12471
   PubMed Web of Science ®Google Scholar
• Shen F, Gaffen SL. Structure-Function relationships in the IL-17 receptor: implications for signal transduction and therapy. Cytokine. 2008 Feb;41(2):92–104. DOI:10.1016/j.cyto.2007.11.013.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019 Apr 16;50(4):892–906. DOI:10.1016/j.immuni.2019.03.021.
   PubMed Web of Science ®Google Scholar
• Ho AW, Gaffen SL. IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol. 2010 Mar;32(1):33–42. DOI:10.1007/s00281-009-0185-0. Epub 2009 Dec 13.
   PubMed Web of Science ®Google Scholar